Hauptseite > Publikationsdatenbank > 8-Bicycloalkyl-CPFPX derivatives as potent and selective tools for in vivo imaging of the A1 adenosine receptor > print

001     1025522
005     20250204113842.0
024 7 _ |a 10.1016/j.ejmech.2024.116380
|2 doi
024 7 _ |a 0009-4374
|2 ISSN
024 7 _ |a 0223-5234
|2 ISSN
024 7 _ |a 1768-3254
|2 ISSN
024 7 _ |a 10.34734/FZJ-2024-02916
|2 datacite_doi
024 7 _ |a 38615410
|2 pmid
024 7 _ |a WOS:001229721600001
|2 WOS
037 _ _ |a FZJ-2024-02916
082 _ _ |a 610
100 1 _ |a Humpert, Swen
|0 P:(DE-Juel1)132740
|b 0
|u fzj
245 _ _ |a 8-Bicycloalkyl-CPFPX derivatives as potent and selective tools for in vivo imaging of the A1 adenosine receptor
260 _ _ |a Amsterdam [u.a.]
|c 2024
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718777971_8199
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Imaging of the A1 adenosine receptor (A1R) by positron emission tomography (PET) with 8-cyclopentyl-3-(3-[18F]fluoropropyl)-1-propyl-xanthine ([18F]CPFPX) has been widely used in preclinical and clinical studies.However, this radioligand suffers from rapid peripheral metabolism and subsequent accumulation of radiometabolites in the vascular compartment. In the present work, we prepared four derivatives of CPFPX byreplacement of the cyclopentyl group with norbornane moieties. These derivatives were evaluated by competition binding studies, microsomal stability assays and LC-MS analysis of microsomal metabolites. In addition, the18F-labeled isotopologue of 8-(1-norbornyl)-3-(3-fluoropropyl)-1-propylxanthine (1-NBX) as the most promising candidate was prepared by radiofluorination of the corresponding tosylate precursor and the resulting radioligand([18F]1-NBX) was evaluated by permeability assays with Caco-2 cells and in vitro autoradiography in rat brain slices. Our results demonstrate that 1-NBX exhibits significantly improved A1R affinity and selectivity whencompared to CPFPX and that it does not give rise to lipophilic metabolites expected to cross the blood-brain-barrier in microsomal assays. Furthermore, [18F]1-NBX showed a high passive permeability (Pc = 6.9 ± 2.9 × 10􀀀 5 cm/s) and in vitro autoradiography with this radioligand resulted in a distribution pattern matching A1R expression in the brain. Moreover, a low degree of non-specific binding (5%) was observed. Taken together, these findings identify [18F]1-NBX as a promising candidate for further preclinicalevaluation as potential PET tracer for A1R imaging.
536 _ _ |a 5253 - Neuroimaging (POF4-525)
|0 G:(DE-HGF)POF4-5253
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Schneider, Daniela
|0 P:(DE-Juel1)156407
|b 1
|u fzj
700 1 _ |a Bier, Dirk
|0 P:(DE-Juel1)131810
|b 2
|u fzj
700 1 _ |a Schulze, Annette
|0 P:(DE-Juel1)131847
|b 3
|u fzj
700 1 _ |a Neumaier, Felix
|0 P:(DE-Juel1)175142
|b 4
|u fzj
700 1 _ |a Neumaier, Bernd
|0 P:(DE-Juel1)166419
|b 5
|e Corresponding author
|u fzj
700 1 _ |a Holschbach, Marcus
|0 P:(DE-Juel1)131824
|b 6
|u fzj
773 _ _ |a 10.1016/j.ejmech.2024.116380
|g Vol. 271, p. 116380 -
|0 PERI:(DE-600)2005170-0
|p 116380
|t European journal of medicinal chemistry
|v 271
|y 2024
|x 0009-4374
856 4 _ |y Restricted
|z StatID:(DE-HGF)0599
|u https://juser.fz-juelich.de/record/1025522/files/8-Bicycloalkyl-CPFPX%20derivatives%20as%20potent%20and%20selective%20tools%20for%20in%20vi....pdf
856 4 _ |y OpenAccess
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1025522/files/Manuscript_revised%20Humpert%20EJOC%202024.pdf
856 4 _ |y Restricted
|x icon
|z StatID:(DE-HGF)0599
|u https://juser.fz-juelich.de/record/1025522/files/8-Bicycloalkyl-CPFPX%20derivatives%20as%20potent%20and%20selective%20tools%20for%20in%20vi....gif?subformat=icon
856 4 _ |y Restricted
|x icon-1440
|z StatID:(DE-HGF)0599
|u https://juser.fz-juelich.de/record/1025522/files/8-Bicycloalkyl-CPFPX%20derivatives%20as%20potent%20and%20selective%20tools%20for%20in%20vi....jpg?subformat=icon-1440
856 4 _ |y Restricted
|x icon-180
|z StatID:(DE-HGF)0599
|u https://juser.fz-juelich.de/record/1025522/files/8-Bicycloalkyl-CPFPX%20derivatives%20as%20potent%20and%20selective%20tools%20for%20in%20vi....jpg?subformat=icon-180
856 4 _ |y Restricted
|x icon-640
|z StatID:(DE-HGF)0599
|u https://juser.fz-juelich.de/record/1025522/files/8-Bicycloalkyl-CPFPX%20derivatives%20as%20potent%20and%20selective%20tools%20for%20in%20vi....jpg?subformat=icon-640
856 4 _ |y OpenAccess
|x icon
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1025522/files/Manuscript_revised%20Humpert%20EJOC%202024.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1025522/files/Manuscript_revised%20Humpert%20EJOC%202024.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1025522/files/Manuscript_revised%20Humpert%20EJOC%202024.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1025522/files/Manuscript_revised%20Humpert%20EJOC%202024.jpg?subformat=icon-640
909 C O |o oai:juser.fz-juelich.de:1025522
|p openaire
|p open_access
|p OpenAPC_DEAL
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)132740
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)156407
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)131810
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131847
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)175142
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)166419
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131824
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5253
|x 0
914 1 _ |y 2024
915 p c |a APC keys set
|0 PC:(DE-HGF)0000
|2 APC
915 p c |a Local Funding
|0 PC:(DE-HGF)0001
|2 APC
915 p c |a DFG OA Publikationskosten
|0 PC:(DE-HGF)0002
|2 APC
915 p c |a DEAL: Elsevier 09/01/2023
|0 PC:(DE-HGF)0125
|2 APC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1200
|2 StatID
|b Chemical Reactions
|d 2023-08-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1210
|2 StatID
|b Index Chemicus
|d 2023-08-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J MED CHEM : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J MED CHEM : 2022
|d 2025-01-07
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 _ _ |a APC
980 1 _ |a APC
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21